Krystal Biotech (KRYS) Operating Margin (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Operating Margin data on file, last reported at 46.12% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin rose 501.0% year-over-year to 46.12%; the trailing twelve-month figure through Mar 2026 stood at 42.8% (up 1022.0% YoY), and the FY2025 full-year result was 41.45%, up 1882.0% from the prior year.
• Operating Margin improved to 46.12% in Q1 2026, from 41.33% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 46.12% in Q1 2026 to a low of 303.8% in Q3 2023.
• A 4-year average of 1.33% and a median of 40.93% in 2025 frame the typical range for Operating Margin.
• Across the five-year window, Operating Margin surged 33060 bps in 2024 and tumbled 406 bps in 2025, its largest moves.
• Tracing KRYS's Operating Margin over 4 years: stood at 7.71% in 2023, then jumped by 489 bps to 45.4% in 2024, then fell by 9 bps to 41.33% in 2025, then advanced by 12 bps to 46.12% in 2026.
• Business Quant data shows KRYS's Operating Margin at 46.12% in Q1 2026, 41.33% in Q4 2025, and 42.3% in Q3 2025.